Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Related DGX
DiaSorin To Acquire Focus Diagnostics' Business From Quest Diagnostics for $300M
Earnings Scheduled For January 28, 2016
INC Research Holdings In The Spotlight As Rumors Of A Suitor Circulate (Seeking Alpha)

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

Mar 2016Credit SuisseInitiates Coverage onNeutral
Mar 2016Mizuho SecuritiesUpgradesNeutralBuy
Oct 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings


Related Articles (DGX)

View Comments and Join the Discussion!